Merck's Zepatier is the latest fixed-dose oral drug taken daily to treat hepatitis C virus (HCV) infection.
New chapter gives overview of pediatric development in each life stage: infancy, toddler, preschool, school-age and adolescent.
Orange, CA, HTC recognized for excellence in programs and best practices among its staff.
New program for hematology nurses to earn the Registered Nurse-Board Certified (RN-BC) credential.
"Current Trends in the Management of Hemophilia," posted on December 22, 2015, is the latest educational opportunity to become available from Medscape.
NHF Nurses' Guide chapter on emergency room care is now available as a PDF.
Study shows higher risk of inhibitors in children using recombinant vs. plasma-derived factor VIII products to treat severe hemophilia A.
NHF's MASAC issues two new documents, one on treatment recommendations and the other on physical therapy guidelines.
FDA approves Baxalta's Vonvendi, the first recombinant von Willebrand factor therapy for patients with VWD.
Rice University researchers confirm the presence of factor VIII in endothelial cells, a potential site for future gene therapy.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car